Australian Federal Court finds biosimilar etanercept manufacturing processes do not infringe Pfizer's ENBREL process patent
The Federal Court of Australia recently found that a patent relating to the manufacturing process for Pfizer's ENBREL (etanercept) product was not infringed by the Respondents' involvement in manufacturing the biosimilar BRENZYS products in Pfizer Ireland Pharmaceuticals Unlimited Company v Samsung Bioepis Co., Ltd (Infringement and Validity) [2026] FCA 1244.